BioVie Inc. announced the appointment of R. Richard Wieland II, MBA as the company's interim Chief Financial Officer. Mr. Wieland has served as the Chief Financial Officer (CFO) for multiple biopharmaceutical companies, including Lyphomed Inc., its acquirer Fujisawa USA (now Astellas Pharma US Inc.), Advanced Life Sciences Holdings Inc., which acquired certain clinical programs from Abbott, and Cytochroma Inc. Mr. Wieland currently sits on the board of an emerging medical device company called Voxello Inc.